SITE015-0129

SITE015 (POL) › SITE015-0129

SITE015-0129

A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE015 (POL) · Dr. Ito
consented 2026-02-02

enrolled

AEs

4

Serious

0

Dropout signal

–

Adverse events

4

Grade 2 Asthenia — outcome: RECOVERED/RESOLVED; onset 2023-03-15 (study day 217); relationship: not assessed

moderate assessed

Grade 2 Dyspnoea — outcome: RECOVERED/RESOLVED; onset 2023-03-12 (study day 214); relationship: NOT RELATED

moderate assessed

Grade 2 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2022-12-21 (study day 133); relationship: not assessed

moderate assessed

Grade 1 Alopecia — outcome: RECOVERED/RESOLVED; onset 2022-08-22 (study day 12); relationship: not assessed

mild assessed

Data queries

0

No data queries. Open queries would appear here for this patient.